Literature DB >> 35934766

IDH1 mutation activates mTOR signaling pathway, promotes cell proliferation and invasion in glioma cells.

Timucin Avsar1,2, Tansu Bilge Kose3, Muhammed Deniz Oksal3, Gizem Turan3, Turker Kilic3,4.   

Abstract

BACKGROUND: Glioma is the most common type of brain tumors and isocitrate dehydrogenase (IDH1) gene is the most prominent molecular marker about the disease prognosis, response to therapy and patient survival. There are conflicting data about the effect of IDH1 mutation on glial cell proliferation, invasion and migration characteristics. The effect of IDH1 mutation on mTOR signaling pathway, which has key roles in tumorigenesis process, is limited and previous data is controversial. We aimed to explore the effect of wild type and mutant IDH1 overexpression on glioma cells and investigated the correlation with mTOR signaling pathway associated genes. METHODS AND
RESULTS: U87-MG and A172 cells were transfected with different IDH1 mutant gene overexpressing (R132H, R132L, R132S, R132C) viral vectors. Cell proliferation, cell invasion and migration analysis as well as quantitative PCR analysis with the mutant glioma cell lines were performed. Forty-two patient derived glioma cells were obtained from patients with different glioma subtypes and cancer cells were enriched by culturing cells. Overexpression of both mutant and wild type IDH1 gene promoted the cell proliferation, but only IDH1 mutation increased cell invasion and migration. The expression of IDH1 mutation activated mTOR signaling via upregulation of WNTA, PRKAA2, GSK3B and MTOR genes as well as phosphorylated mTOR protein level.
CONCLUSIONS: Our results highlighted IDH1 mutation upregulate mTOR signaling pathway and promote cell proliferation, invasion and migration.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Cell invasion; Cell migration; Cell proliferation; Glioma; IDH1; mTOR pathway

Mesh:

Substances:

Year:  2022        PMID: 35934766     DOI: 10.1007/s11033-022-07750-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  30 in total

Review 1.  Chemoradiotherapy in malignant glioma: standard of care and future directions.

Authors:  Roger Stupp; Monika E Hegi; Mark R Gilbert; Arnab Chakravarti
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

2.  An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation.

Authors:  Jinlong Shi; Hao Zuo; Lanchun Ni; Liang Xia; Longxiang Zhao; Mingjie Gong; Dekang Nie; Peipei Gong; Daming Cui; Wei Shi; Jian Chen
Journal:  Neurol Sci       Date:  2013-12-22       Impact factor: 3.307

3.  IDH1, Histone Methylation, and So Forth.

Authors:  Virginie Penard-Lacronique; Olivier A Bernard
Journal:  Cancer Cell       Date:  2016-08-08       Impact factor: 31.743

Review 4.  Targeting the phosphoinositide 3-kinase pathway in cancer.

Authors:  Pixu Liu; Hailing Cheng; Thomas M Roberts; Jean J Zhao
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

5.  Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.

Authors:  Jinlong Shi; Baolan Sun; Wei Shi; Hao Zuo; Daming Cui; Lanchun Ni; Jian Chen
Journal:  Tumour Biol       Date:  2014-10-05

6.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Authors:  Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2009-06-25       Impact factor: 17.088

7.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

8.  IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.

Authors:  Alexandra R Grassian; Seth J Parker; Shawn M Davidson; Ajit S Divakaruni; Courtney R Green; Xiamei Zhang; Kelly L Slocum; Minying Pu; Fallon Lin; Chad Vickers; Carol Joud-Caldwell; Franklin Chung; Hong Yin; Erika D Handly; Christopher Straub; Joseph D Growney; Matthew G Vander Heiden; Anne N Murphy; Raymond Pagliarini; Christian M Metallo
Journal:  Cancer Res       Date:  2014-04-22       Impact factor: 13.312

Review 9.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Pieter Wesseling; Daniel J Brat; Ian A Cree; Dominique Figarella-Branger; Cynthia Hawkins; H K Ng; Stefan M Pfister; Guido Reifenberger; Riccardo Soffietti; Andreas von Deimling; David W Ellison
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 13.029

Review 10.  IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.

Authors:  Hui Yang; Dan Ye; Kun-Liang Guan; Yue Xiong
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.